OBJECTIVE： To observe therapeutic efficacies and safety of diltiazem combined with ciclosporine in the treatment of nephrotic syndrome complicated with acute renal injury. METHODS： A total of 66 patients with nephrotic syndrome and cute kidney injury were randomly divided into control group （30 cases） and observation group （36 cases）. Control group was given routine treatment； observation group was additionally given Diltiazem hydrochloride tablet 5 mg orally， twice a day， and Ciclosporin soft capsules 1.5 mg/（kg·d） orally， twice a day. Treatment course of 2 groups lasted for 20 d. Clinical efficacies of 2 groups were observed. The serum creatinine and kidney injury molecule 1 （KIM-1）， 24 h urine volume， 24 h urine protein levels， AKI classification， follow-up and recurrence were observed before and after treatment as well as the occurrence of ADR. RESULTS： The remission rate of observation group was significantly higher than that of control group， and recurrence rate was significantly lower than control group， with statistical significance （P＜0.05）. Before treatment，there was no statistical significance in the serum creatinine levels，KIM-1，24 h urine pratein， 24 h urine and AKI classification between 2 groups （P＞0.05）. After 2 weeks and 1 month of treatment of observatiom groups， and after 1 month of treatment of control group， serum creatinine levels， KIM-1 and 24 h urine protein of observation group were significantly lower than before treatment， and the observation group was significantly lower than the control group； 24 h urine and the ratio of gradeⅠby AKI classification were significantly more than before treatment， and the observation group was significantly more than the control group， with statistical significance （P＜0.05）. Follow-up rate in 2 groups were 100％，and there was no statistical significance in the incidence of ADR between 2 groups（P＞0.05）. CONCLUSIONS： Based on routine treatment， diltiazem combined with ciclosporin shows significant therapeutic efficacy in the treatment of nephrotic syndrome and acute renal injury with good safety.